TRDA

Entrada Therapeutics, Inc.

Biotechnology · Biotechnology

$341.80 sample

-4.96 (-1.43%) 1D

Market cap

$185.4B

Price as of

2026-10-03

Latest filing

8-K · 2026-09-15

Alerts

8

Price$341.80 +19.04% 3M daily closessample

350.47286.84

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 30INSInsider buy: Chief Executive Officer
Sep 25INSInsider sell: Chief Financial Officer
Sep 22INSInsider sell: General Counsel
Sep 15SEC10-Q filed
Sep 09SEC8-K filed: material event
Sep 03SEC10-Q filed
Aug 26INSInsider sell: 10% owner
Aug 17INSInsider sell: General Counsel

Sign up to see the real TRDA record →

Company facts

SEC EDGAR registration

Name: Entrada Therapeutics, Inc.
Sector: Biotechnology
Industry: Biotechnology
Smart-money score: -50sample, -100 to +100
Reporting currency: USD

Who is positioning in TRDA

sample

Insiders: 29 insider transactions over 90 days, net selling, $435.9M
Congress: 5 members traded over 90 days
Institutions · 13F: 41 funds hold $1.6B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$8.9B +18.8% y/y

Q4 2024Q3 2026

Inventory$5.3B +10.3% y/y

Q4 2024Q3 2026

Accounts receivable$3.8B +8.8% y/y

Q4 2024Q3 2026

Total debt$10.7B +17.9% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $100.4B -5.3% 3M
Sample peer B: $59.6B -9.1% 3M
Sample peer C: $125.4B -11.2% 3M
Sample peer D: $29.5B +2.1% 3M
Sample peer E: $150.6B +8.3% 3M